Your browser doesn't support javascript.
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
Song, Ge; He, Wan-Ting; Callaghan, Sean; Anzanello, Fabio; Huang, Deli; Ricketts, James; Torres, Jonathan L; Beutler, Nathan; Peng, Linghang; Vargas, Sirena; Cassell, Jon; Parren, Mara; Yang, Linlin; Ignacio, Caroline; Smith, Davey M; Voss, James E; Nemazee, David; Ward, Andrew B; Rogers, Thomas; Burton, Dennis R; Andrabi, Raiees.
  • Song G; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • He WT; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
  • Callaghan S; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
  • Anzanello F; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Huang D; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
  • Ricketts J; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
  • Torres JL; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Beutler N; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
  • Peng L; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
  • Vargas S; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Cassell J; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
  • Parren M; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
  • Yang L; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Ignacio C; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Smith DM; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Voss JE; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Nemazee D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Ward AB; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Rogers T; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
  • Burton DR; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
  • Andrabi R; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Nat Commun ; 12(1): 2938, 2021 05 19.
Article in English | MEDLINE | ID: covidwho-1236086
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Pre-existing immunity to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, induced from natural infection or vaccination. A first step to establish whether pre-existing responses can impact SARS-CoV-2 infection is to understand the nature and extent of cross-reactivity in humans to coronaviruses. Here we compare serum antibody and memory B cell responses to coronavirus spike proteins from pre-pandemic and SARS-CoV-2 convalescent donors using binding and functional assays. We show weak evidence of pre-existing SARS-CoV-2 cross-reactive serum antibodies in pre-pandemic donors. However, we find evidence of pre-existing cross-reactive memory B cells that are activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, including SARS-CoV-1 and endemic coronaviruses. We identify one cross-reactive neutralizing antibody specific to the S2 subunit of the S protein. Our results suggest that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Cross Protection / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-23074-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Cross Protection / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-23074-3